Satoshi Kobayashi

Kanagawa Cancer Center
Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (17)

Year:

2026

Year:

2026

Year:

2025

Year:

2025

PURPOSE Modified fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX) and nab-paclitaxel + gemcitabine are recommended as first-line treatments for metastatic pancreatic cancer. S-1, irinotecan, and oxaliplatin (S-IROX) demonstrated activity in a phase Ib trial in this population. Therefore, these three regimens were directly compared. METHODS This randomized phase II/III trial was performed at 45 centers in Japan. Eligible patients age 20-75 years with an Eastern Cooperative Oncology Group performance status of 0 or 1 and pathologically confirmed metastatic or recurrent pancreatic cancer were randomly assigned (1:1:1) to receive mFOLFIRINOX (oxaliplatin 85 mg/m 2 over 2 hours, irinotecan 150 mg/m 2 over 90 minutes, l-leucovorin 200 mg/m 2 over 2 hours, each once daily on day 1, and fluorouracil 2,400 mg/m 2 over 46 hours on days 1-3, every 2 weeks), S-IROX (oxaliplatin 85 mg/m 2 over 2 hours, irinotecan 150 mg/m 2 over 90 minutes on day 1, and S-1 80 mg/m 2 /day administered orally twice daily on days 1-7, every 2 weeks), or nab-paclitaxel (125 mg/m 2 ) + gemcitabine (1,000 mg/m 2 ) on days 1, 8, and 15 every 4 weeks. The primary end point was overall survival (OS). RESULTS A total of 527 patients were enrolled, with 426 included in the planned interim analysis. The median OS was 14.0 months (hazard ratio [HR], 1.31 [95% CI, 0.97 to 1.77]) and 13.6 months (HR, 1.35 [95% CI, 1.00 to 1.82]) in the mFOLFIRINOX and S-IROX groups, respectively, as compared with 17.1 months in the nab-paclitaxel + gemcitabine group. The predictive probability of achieving superiority in the final analysis was <1% in both groups. Thus, the trial was terminated owing to its futility. Grade 3 to 4 anorexia was more frequent in the mFOLFIRINOX (23.3%) and S-IROX (27.5%) groups than in the nab-paclitaxel + gemcitabine group (5.0%). CONCLUSION Neither mFOLFIRINOX nor S-IROX appeared to be superior compared with nab-paclitaxel + gemcitabine as the first-line treatment for metastatic or recurrent pancreatic cancer.

Year:

2025

Background Systemic chemotherapy with gemcitabine plus S-1 (GEM + S-1), GEM + CDDP plus S-1 (GEM + CDDP + S-1), or gemcitabine plus cisplatin (GEM + CDDP) is standard treatment for advanced biliary tract cancer (aBTC). We aimed to evaluate the efficacy and safety of combination chemotherapy in older patients with aBTC. Methods This multicenter prospective observational study (JON2104-B, UMIN000045156) included patients aged ≥ 70 years with aBTC. Inverse-probability weighting propensity-score analyses (IPW) were used to compare overall survival (OS) as the primary endpoint and progression-free survival (PFS) across treatment groups. Results This study included 305 patients between August 2021 and January 2023. Of them, 75, 131, 26, 52, and 10 received GEM + CDDP + S-1, GEM + CDDP, GEM + S-1, gemcitabine, and S-1; their median ages were 74, 75, 77.5, 80, and 80 years, and approximately 24%, 16.8%, 23.1%, 9.6%, and 0% had G-8 scores of > 14, respectively. GEM + CDDP had a safety profile comparable to that of GEM + CDDP + S-1 but was more toxic than gemcitabine. Per IPW, the hazard ratio (HR) for GEM + CDDP + S-1 versus GEM + CDDP was 0.80 for OS (95% confidence interval [CI], 0.55–1.17) and 0.55 for PFS (95% CI 0.38–0.80). The HR for GEM + CDDP versus gemcitabine was 0.74 for OS (95% CI 0.42–1.29) and 0.79 for PFS (95% CI 0.42–1.49). Conclusions GEM + CDDP + S-1 was associated with longer PFS without additional toxicity than GEM + CDDP for fit older patients. However, the OS for both were not statistically different. The efficacies of GEM + CDDP and gemcitabine for vulnerable older patients did not also differ significantly. These findings highlight the importance of vulnerability in patients with aBTC.

Year:

2025

Aims Carbon‐ion radiation therapy (CIRT) is a promising technological innovation for treating hepatocellular carcinoma (HCC). This study aimed to evaluate the effectiveness and safety of CIRT for primary, solitary, potentially resectable HCC in comparison to liver resection (LR). Methods and Results We retrospectively compared treatment effectiveness and safety between patients treated with CIRT and those who underwent LR for potentially resectable HCC at our institution. The clinical data for the CIRT group were obtained from a prospective observational study carried out at our institution, and additional information was obtained from clinical records. Their data were compared with those of patients who underwent LR during the same period. Twenty‐three patients were included in the CIRT group and 41 in the LR group. In the overall cohort, the respective 3‐and 5‐year overall survival (OS) rates were 86.5% and 65.9% for the CIRT group and 90.2% and 79.7% for the LR group. The OS rates did not significantly differ between the two groups in the propensity score‐matched cohort. The 3‐ and 5‐year local control rates after CIRT were 77.0% and 77.0%, respectively. CIRT was associated with elevated albumin‐bilirubin (ALBI) scores 3 and 6 months after treatment. Conclusion CIRT for primary, solitary, potentially resectable HCC was associated with favorable clinical outcomes and satisfactory safety, with an acceptable elevation of the ALBI score. CIRT might achieve a favorable OS comparable to LR for potentially resectable HCC; however, further large‐scale, prospective studies are needed for confirmation.

Year:

2025

Background: Nanoliposomal irinotecan combined with fluorouracil plus leucovorin (nal-IRI + 5-FU/LV) is a standard second-line treatment for patients with advanced pancreatic cancer. Despite its efficacy, the prognostic factors for treatment efficacy remain unclear in clinical practice. Objectives: To investigate prognostic factors for survival with nal-IRI + 5-FU/LV. Design: Single-centre retrospective cohort. Methods: We included 204 patients who were treated with nal-IRI + 5-FU/LV at our institution between July 2020 and March 2022. These patients had unresectable or recurrent pancreatic adenocarcinoma refractory to a gemcitabine-containing regimen. A Cox regression hazard model was used to explore prognostic factors for overall survival (OS). Results: Of the 204 eligible patients, 127 (64%) had received only one prior treatment. Most patients (90%) had metastatic disease, with 93, 61 and 55 patients having metastases to the liver, lungs and peritoneum, respectively. Among them, 18 patients had peritoneal metastasis without ascites. The median OS and progression-free survival (PFS) were 8.7 (95% confidence interval (CI), 7.5–9.8) and 3.6 (95% CI, 3.0–4.2) months, respectively. An Eastern Cooperative Oncology Group performance status (PS) of 0, serum albumin (Alb) level ⩾3.5 g/dL, C-reactive protein (CRP) level 3.5 g/dL, CRP <0.5 mg/dL, CA 19-9 <1000 U/mL and the presence of peritoneal metastasis, especially without ascites, were favourable prognostic factors for survival in patients with advanced pancreatic cancer treated with nal-IRI + 5-FU/LV.

Year:

2025

Background Although the combination of atezolizumab and bevacizumab (ATZ + BEV) is a standard treatment for advanced hepatocellular carcinoma (HCC), strategies for addressing treatment failure and prognostic factors of post‐progression survival (PPS) remain unestablished. Methods We conducted a multicentre retrospective study to evaluate PPS following ATZ + BEV treatment in patients with advanced HCC. We classified the patients into three groups: BCLC stage B and BCLC stage C without or with new extrahepatic lesions (BCLCp‐C1 and BCLCp‐C2, respectively) at the time of progression. Results Of the 204 patients who started ATZ + BEV treatment between October 2020 and September 2022, 110 showed disease progression, with 33, 55 and 22 showing the BCLCp‐B, BCLCp‐C1 and BCLCp‐C2 stages of the disease, respectively. Specifically, patients with the BCLCp‐B stage of the disease showed better overall survival than those with the BCLCp‐C1 and BCLCp‐C2 stages (hazard ratios: 1.93 [95% confidence interval, CI, 1.06–3.51] and 2.64 [95% CI, 1.32–5.30] for HCC stages BCLCp‐C1 and BCLCp‐C2, respectively). Via multivariable analysis, we identified the BCLCp‐C1 and BCLCp‐C2 stages, as well as performance status, Child–Pugh class and alpha‐fetoprotein as poor prognostic factors for PPS. Conclusions BCLCp‐B1 stage was identified as a better prognostic factor for PPS following ATZ + BEV treatment compared with BCLCp‐C1 and BCLCp‐C2 stages. This may help in making decisions regarding subsequent treatment after ATZ + BEV.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (11)

Shunsuke Kondo

Professor

Tokyo Women's Medical University

JAPAN
View details

Taroh Satoh

Professor

Osaka University Hospital

JAPAN
View details

Ichiro Yasuda

Director and Professor

University of Toyama

JAPAN
View details

Shin Maeda

-

JAPAN
View details

Yasuhito Tanaka

M.D., Ph.D

Kumamoto University

JAPAN
View details

Hisashi Hidaka

Kitasato University School of Medicine

JAPAN
View details

Conrad Achilonu

Researcher

Mayo Clinic

UNITED STATES
View details

Akiko Todaka

Oita University

JAPAN
View details

Yoshito Komatsu

Hokkaido University Hospital

JAPAN
View details

Tatehiro Kagawa

Professor

Tokai University School of Medicine

JAPAN
View details

Kota Tsuruya

Tokai University

JAPAN
View details